Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

NCT: NCT07179003 · NOT_YET_RECRUITING

NCT IDNCT07179003
StatusNOT_YET_RECRUITING
Start Date2027-07
Completion2032-06
SponsorUniversity of Rochester (OTHER)
First posted
Last updated

Brief Summary

The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous breast abscess drainage for disinfection of breast abscesses. The study includes two arms: (1) standard of care breast abscess drainage and (2) MB-PDT plus standard of care breast abscess drainage. The primary endpoint is time to resolution of clinical symptoms. Secondary endpoints include imaging evidence of abscess resolution, abscess recurrence, need for repeated intervention, and cure rate across treatment groups. Responses will be compared between the two study arms for the per protocol population to determine the efficacy of MB-PDT relative to standard of care. The investigators hypothesize that the addition of MB-PDT to standard of care will significantly reduce the time to symptom resolution, compared to standard of care alone.

Frequently Asked Questions

What is A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses?

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses is a clinical trial registered under NCT07179003. Current status: NOT_YET_RECRUITING.

What is the status of NCT07179003?

The current status of NCT07179003 (A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses) is: NOT_YET_RECRUITING.

When did A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses start?

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses started on 2027-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.